pp 1–6 | Cite as

Acidophil stem cell pituitary adenoma: a case report and literature review

  • Anupriya AnnapurniEmail author
  • Manjusha Rathi
Case Report


In this article, we describe a very rare case of pituitary acidophilic stem cell adenoma, accompanied by a literature review. We present the case of 33-year-old woman with a history of amenorrhea, galactorrhea, elevated prolactin levels, and pituitary tumor. Despite suppression of prolactin levels with cabergoline, the pituitary tumor continued to increase in size and the patient developed clinical symptoms and biochemistry consistent with the diagnosis of acromegaly due to acidophilic stem cell adenoma, an extremely rare subtype of mixed growth hormone/prolactin adenoma, which behaves more aggressively and has a lower surgical cure rate compared to the pure GH-secreting adenoma. The patient had in vitro fertilization 2 years after the successful pituitary surgery and delivered healthy twins. To our knowledge, this is the only case report which describes acromegaly developing during cabergoline treatment. This case also highlights the importance of having a correct histopathological diagnosis to determine the behavior of the tumor and decide on further management.


Acidophilic Pituitary adenoma Acromegaly Pituitary stem cell adenoma 



In vitro fertilization


Insulin growth factor 1


Oral glucose tolerance test


Growth hormone




Magnetic resonance imaging


Follicular stimulating hormone


Luteinizing hormone


Serum hormone-binding globulin


Thyroid-stimulating hormone


Free thyroxine


Free tri-iodothyronine


Adrenocorticotrophic stimulating hormone


Hemoglobin A1c






Micro units/liter










Acute medical admission unit



Both Anupriya Annapurni and Manjusha Rathi contributed to the planning of the manuscript, the review of the literature, and the writing and review of the original and final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no potential conflicts of interest.

Statement of informed consent

Informed consent has been obtained from the patient for publication of the case report and accompanying images.


  1. 1.
    Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG, Birkenhager JC (1982) The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Investig 12:151–155CrossRefGoogle Scholar
  2. 2.
    Kovacs K, Asa SL (1991) Functional endocrine pathology, vol 1. Blackwell Scientific Publications, Oxford, pp 182–183Google Scholar
  3. 3.
    De Lellies RA, Llyod RV, Heitz PU, Eng C (2004) World Health Organization classification of tumors: pathology and genetics of tumors of endocrine organs, 3rd edn. IARC Press, LyonGoogle Scholar
  4. 4.
    Beatriz M, Lopes S (2010) Growth hormone-secreting adenomas: pathology and cell biology. JNS Neurosurg Focus 29(4):E2. CrossRefGoogle Scholar
  5. 5.
    Dios E, Martínez MA, Soto A, Japón MA, Villamil F (2005) Acidophil stem cell adenoma: an uncommon pituitary tumour. Endocrinol Nutr 5:379–383CrossRefGoogle Scholar
  6. 6.
    Fazekas I, Pásztor E, Slowik F et al (1993) Pathological and experimental investigations in a case of gigantism. Acta Neuropathol 85:167–174CrossRefGoogle Scholar
  7. 7.
    Maheshwari HG, Prezant TR, Vivien et al (2000) Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 85(9):3409–3416PubMedGoogle Scholar
  8. 8.
    Horvath E, Kovacs K et al (1981) Acidophil stem cell adenoma of the human pituitary: clinicopathological analysis of 15 cases. Cancer 47:761CrossRefGoogle Scholar
  9. 9.
    Kalk WJ, D'Costa RV (2005) Bromocriptine -sensitive acidophil-stem-cell adenoma co-secreting growth hormone and prolactin - a case report. Endocr Abstr 9:P198Google Scholar
  10. 10.
    Lim JS, Ku CR, Lee MK et al (2010) A case of fugitive acromegaly, initially presented as invasive prolactinoma. Endocr 38:1 CrossRefGoogle Scholar
  11. 11.
    Marks WA, Brumback RA, Schaefer G, Pendleton BD, Farris BK, Culbertson JL (1989) Acidophil stem-cell pituitary adenoma in a prepubescent female. J Neurosurg 70(2):266–270CrossRefGoogle Scholar
  12. 12.
    Pereira BD, Raimundo L, Mete O et al Monomorphous plurihormonal pituitary adenoma of Pit-1 lineage in a giant adolescent with central hyperthyroidism. Endocr Pathol 46(27):25 CrossRefGoogle Scholar
  13. 13.
    Rajasekaran S, Vanderpump M, Wass J et al (2010) UK guidelines for the management of pituitary apoplexy. Clin Endocrinol.
  14. 14.
    Chatzellis E, Alexandraki KI, Androulakis I, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87–104CrossRefGoogle Scholar
  15. 15.
    Scheithauer BW, Horvath E, Lloyd RV, Kovacs K (2001) Pathology of pituitary adenomas and pituitary hyperplasia. In: Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (eds) Diagnosis and Management Pituitary Tumors. Humana Press, Totowa, pp 91–154Google Scholar
  16. 16.
    Kovacs K, Horvath E (1987) Pathology of pituitary tumors. Endocrinol Metab Clin N Am 16:529–551CrossRefGoogle Scholar
  17. 17.
    Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe H-J, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. CrossRefPubMedGoogle Scholar
  18. 18.
    Kreutzer J, Vance ML, Lopes MBS, Laws ER (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86(9):4072–4077.6.26CrossRefGoogle Scholar
  19. 19.
    Horvath E, Kovacs K et al (1977) Acidophilic stem cell adenoma of the human pituitary. Arch Pathol Lab Med 101:594–599PubMedGoogle Scholar
  20. 20.
    Mete O, Ezzat S, Asa S (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49(2):R69–R78CrossRefGoogle Scholar
  21. 21.
    Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategiers. Eur J Endocrinol 170(4):R121–R132CrossRefGoogle Scholar
  22. 22.
    Horvath E, Kovács K (1992) The ultra structural diagnosis of pituitary adenomas. Microsc Res Tech 20(2):107–135CrossRefGoogle Scholar
  23. 23.
    Giuffrida G, Ferrau F et al (2019) Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocrine Connect 8(5):528–535CrossRefGoogle Scholar
  24. 24.
    An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH (2003) Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49–62CrossRefGoogle Scholar
  25. 25.
    Sandret L, Maison P et al (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1327–1335. CrossRefPubMedGoogle Scholar
  26. 26.
    Rickels MR, Snyder PJ (2004) Cabergoline decreases somatotrophadenoma size: a case report. Pituitary 7:107–110CrossRefGoogle Scholar
  27. 27.
    Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552–561CrossRefGoogle Scholar
  28. 28.
    Page MD, Bridges LR, Barth JH et al (1996) Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. J Clin Endocrinol Metab 81:4484–4487. CrossRefPubMedGoogle Scholar
  29. 29.
    Badawy SZ, Anderson GH Jr, Shende MC, Marshall L (1984) Development of acromegaly in a patient with prolactinemia: a case study. Fertil Steril 42(6):926–928CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2019

Authors and Affiliations

  1. 1.Department of Diabetes and Endocrinology, Queen’s Medical CentreNottingham University Hospitals NHS TrustNottinghamUK
  2. 2.Department of Diabetes and EndocrinologyKing’s Mill Hospital, Sherwood Forest Hospitals NHS Foundation TrustNottinghamshireUK

Personalised recommendations